InsiderSignal.AI

InsiderSignal.ai

JSPR - Jasper Therapeutics, Inc.

Insider Purchase by Shizuru Judith Anne (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Shizuru Judith Anne, serving as Dir at Jasper Therapeutics, Inc. (JSPR), purchased 41,000 shares at $2.43 per share, for a total transaction value of $99,630.00. Following this transaction, Shizuru Judith Anne now holds 156,901 shares of JSPR.

This purchase represents a 35.00% increase in Shizuru Judith Anne's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, September 22, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, September 24, 2025, 2 days after the trade was made.

Jasper Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Shizuru Judith Anne

Dir

Judith Anne Shizuru (also known as Judith Shizuru) is a Professor of Medicine in Blood and Marrow Transplantation at Stanford University, specializing in hematopoietic cell transplantation (HCT), stem cell biology, and regenerative medicine.[[2]](https://profiles.stanford.edu/judith-shizuru)[[4]](https://med.stanford.edu/profiles/judith-shizuru) She earned her MD and PhD from Stanford University School of Medicine in 1992, completed residency at UCSF in 1994, and fellowship at Stanford in 1997, and holds board certification in Internal Medicine.[[2]](https://profiles.stanford.edu/judith-shizuru) Her research focuses on improving HCT safety and efficacy by developing novel engraftment methods for blood-forming stem cells to replace chemotherapy and radiation, and she has attended on Stanford's BMT clinical service since 1997.[[2]](https://profiles.stanford.edu/judith-shizuru)[[4]](https://med.stanford.edu/profiles/judith-shizuru) Dr. Shizuru serves as Director at Jasper Therapeutics, Inc. (JSPR) since 2018, Chair of its Scientific Advisory Board since 2019, and is also on the Scientific Advisory Board of Shoreline Biosciences.[[1]](https://www.gurufocus.com/insider/178318/judith-anne-shizuru)[[2]](https://profiles.stanford.edu/judith-shizuru)[[3]](https://stanfordhealthcare.org/doctors/s/judith-shizuru.html)[[6]](https://jaspertx.com/team/) She owns approximately 156,901 shares of JSPR stock valued at over $298,112 as of recent data and has recently acquired additional common shares as a corporate insider.[[1]](https://www.gurufocus.com/insider/178318/judith-anne-shizuru)[[5]](https://longbridge.com/en/news/258756538) Her career highlights include multiple Burroughs Wellcome Fund and Howard Hughes Medical Institute awards, and leadership in clinical trials for AML and MDS using briquilimab (JSP191).[[2]](https://profiles.stanford.edu/judith-shizuru)[[3]](https://stanfordhealthcare.org/doctors/s/judith-shizuru.html)

View full insider profile →

Trade Price

$2.43

Quantity

41,000

Total Value

$99,630.00

Shares Owned

156,901

Trade Date

Monday, September 22, 2025

153 days ago

SEC Filing Date

Wednesday, September 24, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Jasper Therapeutics, Inc.

Company Overview

No company information available
View news mentioning JSPR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/476526

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime